Biomea Fusion Inc (BMEA) Stock Analysis

Biomea Fusion Inc (BMEA) is a publicly traded company in the HEALTHCARE sector. It trades at $1.37, carries a market capitalization of $99.77M. This page summarizes the public market data, fundamentals, and frequently asked questions for BMEA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.37
• Market Cap: $99.77M
• EPS: $-0.55
• 52-Week High: $3.08
• 52-Week Low: $0.87

Market Sentiment

Biomea Fusion Inc currently has a Bullish sentiment score of 0.38.

About Biomea Fusion Inc

Biomea Fusion Inc. is an innovative biopharmaceutical company headquartered in Redwood City, California, focused on developing cutting-edge irreversible small molecules for the treatment of genetically defined cancers. By harnessing advanced scientific methodologies, Biomea aims to meet the significant unmet medical needs of patients with specific genetic mutations, thereby establishing itself as a leader in the field of targeted cancer therapies. With a robust clinical pipeline and a strateg...

GNG Research Analysis

GNG Research scores Biomea Fusion Inc (BMEA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BMEA.

Frequently Asked Questions

Does BMEA pay dividends?

Biomea Fusion Inc (BMEA) does not currently pay a regular dividend.

What is BMEA's market cap?

Biomea Fusion Inc (BMEA) has a market capitalization of $99.77M with a current stock price of $1.37.